Kontaktujte nás | Jazyk: čeština English
dc.title | Progresivní multifokální leukoencefalopatie – Epidemiologie, imunitní odpověď, klinické rozdíly, léčba | cs |
dc.title | Progressive multifocal leukoencephalopathy - Epidemiology, immune response, clinical differences, treatment | en |
dc.contributor.author | Snopková, Svatava | |
dc.contributor.author | Štourač, Petr | |
dc.contributor.author | Fašaneková, Lenka | |
dc.contributor.author | Mihalčin, Matúš | |
dc.contributor.author | Havlíčková, Kateřina | |
dc.contributor.author | Svačinka, Radek | |
dc.contributor.author | Volfová, Pavlína | |
dc.contributor.author | Snopek, Petr | |
dc.contributor.author | Husa, Petr | |
dc.relation.ispartof | Epidemiologie, Mikrobiologie, Imunologie | |
dc.identifier.issn | 1210-7913 Scopus Sources, Sherpa/RoMEO, JCR | |
dc.date.issued | 2019 | |
utb.relation.volume | 2019 | |
utb.relation.issue | 1 | |
dc.citation.spage | 24 | |
dc.citation.epage | 31 | |
dc.type | article | |
dc.language.iso | en | |
dc.publisher | Czech Medical Association J.E. Purkyne | |
dc.relation.uri | https://www.prolekare.cz/en/journals/epidemiology-microbiology-immunology/2019-1-20/progressive-multifocal-leukoencephalopathy-epidemiology-immune-response-clinical-differences-treatment-112627 | |
dc.subject | CD4/CD8 ratio | en |
dc.subject | cellular immunity | en |
dc.subject | HIV | en |
dc.subject | multiple sclerosis | en |
dc.subject | progressive multifocal leukoencephalopathy | en |
dc.description.abstract | Progressive multifocal leukoencephalopathy (PML) is a severe disease of the central nervous system with very high mortality. It is caused by the JC virus with high seroprevalence, at up to 80%. Development of PML is typically opportunistic, particularly in acquired immunodeficiency syndrome, and usually affects patients with profound immunodeficiency. Furthermore, as a result of highly efficient immunosuppressive and immunomodulatory treatments in recent years, the number of PML cases has increased in the general population. In this article, the authors mention virological and epidemiological relationships and characteristic manifestations of PML. Possible relationships of humoral and cellular immunity are discussed and limited treatment options including prophylaxis are mentioned. © 2019, Czech Medical Association J.E. Purkyne. All rights reserved. | en |
utb.faculty | Faculty of Humanities | |
dc.identifier.uri | http://hdl.handle.net/10563/1009046 | |
utb.identifier.obdid | 43880572 | |
utb.identifier.scopus | 2-s2.0-85068462634 | |
utb.identifier.wok | 000471143400004 | |
utb.identifier.pubmed | 31181949 | |
utb.identifier.coden | EMIME | |
utb.source | j-scopus | |
dc.date.accessioned | 2019-09-19T07:56:13Z | |
dc.date.available | 2019-09-19T07:56:13Z | |
utb.contributor.internalauthor | Snopek, Petr | |
utb.fulltext.affiliation | Snopková S. 1, Štourač P. 2, Fašaneková L. 1, Mihalčin M. 1, Havlíčková K. 1, Svačinka R. 1, Volfová P., Snopek P., Husa P. 1 1 Klinika infekčních chorob FN Brno a LF MU, Brno 2 Kliniky dětské anesteziologie a resuscitace FN Brno a LF MU doc. | |
utb.fulltext.dates | Do redakce došlo dne 19. 3. 2018. | |
utb.scopus.affiliation | Klinika infekčních chorob FN Brno a LF MU, Brno, Czech Republic; Neurologická klinika FN Brno a LF MU, Brno, Czech Republic; Interní hematoonkologická klinika FN Brno a LF MU, Brno, Czech Republic; Fakulta humanitních studií UTB, Zlín, Czech Republic |